Bove Mauro 4
4 · REGENERX BIOPHARMACEUTICALS INC · Filed Oct 20, 2020
Insider Transaction Report
Form 4
Bove Mauro
Director
Transactions
- Purchase
Convertible Promissory Note (right to buy)
2020-10-15$10000.00/shExercise: $0.36From: 2020-10-15Exp: 2025-10-15→ Common Stock (27,840 underlying) - Purchase
Common Stock Warrant (right to buy)
2020-10-15+20,880→ 20,880 totalExercise: $0.45From: 2021-04-15Exp: 2025-10-15→ Common Stock (20,880 underlying)
Holdings
- 150,000
Stock Option (right to buy)
Exercise: $0.21Exp: 2021-03-25→ Common Stock (150,000 underlying) - 100,000
Stock Option (right to buy)
Exercise: $0.36Exp: 2022-06-30→ Common Stock (100,000 underlying) - 125,000
Stock Option (right to buy)
Exercise: $0.28Exp: 2027-09-01→ Common Stock (125,000 underlying) Convertible Promissory Note (right to buy)
Exercise: $0.12From: 2019-02-27Exp: 2024-02-27→ Common Stock (41,667 underlying)- 31,250
Common Stock Warrant (right to buy)
Exercise: $0.18From: 2019-08-27Exp: 2024-02-27→ Common Stock (31,250 underlying) - 100,000
Stock Option (right to buy)
Exercise: $0.19Exp: 2022-02-11→ Common Stock (100,000 underlying) - 200,000
Stock Option (right to buy)
Exercise: $0.21Exp: 2029-05-15→ Common Stock (200,000 underlying) - 100,000
Stock Option (right to buy)
Exercise: $0.64Exp: 2023-03-16→ Common Stock (100,000 underlying) - 31,250
Common Stock Warrant (right to buy)
Exercise: $0.18From: 2019-11-13Exp: 2024-05-13→ Common Stock (31,250 underlying) - 200,000
Stock Option (right to buy)
Exercise: $0.21Exp: 2028-07-17→ Common Stock (200,000 underlying) - 200,000
Stock Option (right to buy)
Exercise: $0.30Exp: 2030-06-10→ Common Stock (200,000 underlying) Convertible Promissory Note (right to buy)
Exercise: $0.12From: 2019-05-13Exp: 2024-05-13→ Common Stock (41,667 underlying)
Footnotes (4)
- [F1]100% vested.
- [F2]50,000 shares vest on each of 7/17/18, 7/17/19, 7/17/20 and 7/17/21.
- [F3]50,000 shares vest on each of 5/15/19, 5/15/20, 5/15/21 and 5/15/22.
- [F4]50,000 shares vest on each of 6/10/20, 6/10/21, 6/10/22 and 6/10/23.